All In MedTech

Device Trial Radar · NCT07202117

PLLA and CaHA-R for Aesthetic Rejuvenation

Comparing Outcomes of Collagen Biostimulatory Agents: A Randomized, Patient and Evaluator-blinded Clinical Trial Evaluating Poly-L-lactic Acid and Calcium Hydroxyapatite for Rejuvenation of the Face and Body

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Sep 21, 2026

Primary completion

Sep 21, 2028

Study completion Oct 1, 2028

Sponsor

Lead sponsor
Erevna Innovations Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 1, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 21 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Skin ageing is intricately linked to collagen degradation caused by internal and external factors. External factors contributing to ageing include ultraviolet rays, smoking, heat, and air pollution, and follow a distribution across the body according to the level of exposure. Whereas internal ageing occurs as a natural consequence of physiological changes over time. As we age, both natural internal and external factors cause stress to the body. This stress damages important molecules in our skin, including proteins, fats (lipids), and DNA. One of the main proteins affected is collagen, which gives skin its strength and firmness. This loss of collagen leads to visible signs of aging such as wrinkles, thinner skin (atrophy), rough or damaged texture (elastosis), and uneven skin tone (dyschromia). Interventions such as collagen stimulators have shown promising outcomes in stimulating cells to produce collagen, thereby improving skin elasticity and firmness. Poly-L-Lactic Acid is a biodegradable long-chain polymer of repeating units of lactic acid derived from alpha-hydroxy acid. Injecting PLLA into the deep dermis or subcutaneous tissue, stimulates collagen production through an inflammatory response, resulting in skin rejuvenation that can last between two to three years. In contrast, CaHA-R drives the regeneration of collagens, elastin, and proteoglycans with minimal immune cell recruitment and immediate volume improvement lasting around 12-18 months. To date, there have been no randomized-controlled-trials comparing the efficacy of PLLA vs CaHa-R for skin rejuvenation in the face and body.

Conditions

  • Aesthetic

Interventions

  • Sculptra AestheticDevice

    Sculptra® Aesthetic is manufactured by Galderma Laboratories. It is a sterile, lyophilized preparation of PLLA that is biocompatible and biodegradable. Each vial contains 367.5 mg of freeze-dried powder, including 150 mg of PLLA. Prior to injection, it will be reconstituted with sterile water for injection (SWFI) and lidocaine hydrochloride (2%). For this study, commercial products will be used. The study products are for single use only.

  • RadiesseDevice

    Radiesse® is manufactured by Merz Aesthetics. It is a sterile, non-pyrogenic, semi-solid injectable implant composed of synthetic CaHA suspended in a gel carrier of sterile water, glycerin, and sodium carboxymethylcellulose. Each pre-filled syringe contains 1.5 mL of product. The product includes 0.3% lidocaine for pain reduction during injection. For this study, commercial products will be used. The study products are for single use only.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Skin Elasticity Measured by CutometerTime frame: Baseline (Visit 1) to Week 40 (Visit 6)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Erevna Innovations Inc.

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.